Sedia Biosciences to present results of HIV incidence assay at International AIDS Conference

NewsGuard 100/100 Score

Sedia Biosciences Corporation of Portland, Oregon will be presenting its first public results of a new rapid point-of-care HIV incidence assay at the upcoming 20th International AIDS Conference in Melbourne, Australia, July 21-25, 2014. The new assay is expected to augment Sedia's suite of commercial HIV incidence products and further establish Sedia's leadership in the development and manufacture of laboratory assays to monitor the epidemic around the world. The presentation, given as a scientific poster, is entitled "Characterization of a rapid HIV-1 incidence assay based on a CDC-developed multi-subtype antigen in a commercial HIV lateral flow assay format."

The poster presentation (Poster # WEPE105) will be hosted by Sedia's Director of Product Support and Technical Services, Paul Smith from 12:30 pm to 2:30 pm on Wednesday, July 23, 2014. Mr. Smith stated "This is an exciting new concept incorporating Sedia's rapid test technology with components of the Sedia™ HIV-1 LAg-Avidity EIA to bring HIV incidence testing to resource limited settings. We are currently working with the Centers for Disease Control and Prevention (CDC) to fully develop this as a new commercial product." The new assay incorporates technology developed by both the CDC and Sedia. Co-authors for the presentation are Dr. Ronald Mink, President and Chief Science Officer, and Stephen Piacentini, Director of Assay Development, who are also attending the conference, and Mimi Jackson, Research Assistant. The poster will also be available for general viewing all day, Wednesday, from 9:00 am to 6:00 pm.

Sedia Biosciences will also be exhibiting its products at the Commercial Exhibition Hall of the International AIDS Conference from Sunday, July 20 through Thursday, July 24. Dr. Mink stated, "This conference presents a unique and important opportunity for Sedia to not only present its HIV products to scientists, policymakers and public health officials working in that field, but to also make them aware of our other products and technologies that can further advance their scientific efforts. We look forward to seeing many of our old friends that have partnered with Sedia over the years, but also to making new friends and building new relationships."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Immunocompromised patients show prolonged SARS-CoV-2 infection and unique mutations